Winthrop Advisory Group LLC Makes New $221,000 Investment in Amgen Inc. (NASDAQ:AMGN)

Winthrop Advisory Group LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 685 shares of the medical research company’s stock, valued at approximately $221,000.

A number of other large investors also recently bought and sold shares of AMGN. Vista Capital Partners Inc. purchased a new position in Amgen during the third quarter valued at $238,000. Lewis Asset Management LLC lifted its stake in Amgen by 24.1% in the 3rd quarter. Lewis Asset Management LLC now owns 1,498 shares of the medical research company’s stock valued at $483,000 after buying an additional 291 shares in the last quarter. Trinity Legacy Partners LLC increased its stake in Amgen by 1.6% during the 3rd quarter. Trinity Legacy Partners LLC now owns 15,382 shares of the medical research company’s stock worth $4,993,000 after buying an additional 239 shares in the last quarter. Tandem Investment Advisors Inc. raised its holdings in shares of Amgen by 107.4% during the third quarter. Tandem Investment Advisors Inc. now owns 1,655 shares of the medical research company’s stock valued at $534,000 after acquiring an additional 857 shares during the last quarter. Finally, Dudley Capital Management LLC purchased a new position in shares of Amgen in the third quarter valued at approximately $303,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on AMGN shares. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 price target on shares of Amgen in a research report on Thursday, September 26th. StockNews.com upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. TD Cowen upped their price objective on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $405.00 target price on shares of Amgen in a research note on Tuesday, October 22nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $380.00 price target (up previously from $375.00) on shares of Amgen in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $333.50.

Amgen Stock Up 0.0 %

NASDAQ:AMGN opened at $321.91 on Friday. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The stock’s fifty day moving average is $323.96 and its two-hundred day moving average is $316.68. The stock has a market capitalization of $173.04 billion, a price-to-earnings ratio of 41.22, a price-to-earnings-growth ratio of 2.79 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period in the prior year, the firm earned $4.96 earnings per share. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year. Research analysts anticipate that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a $2.25 dividend. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 annualized dividend and a dividend yield of 2.80%. Amgen’s dividend payout ratio (DPR) is 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.